2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies

BACKGROUND: Monthly injectable CAB LA + RPV LA was noninferior to daily oral 3-drug antiretroviral therapy in HIV-1 virologically suppressed adults. CAB and RPV pharmacokinetics (PK) were assessed during the 48 Week maintenance period of the ATLAS and FLAIR Phase 3 studies. METHODS: Patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Parul, Ford, Susan L, Crauwels, Herta, Han, Kelong, Rossenu, Stefaan, Neyens, Martine, Griffith, Sandy, Hudson, Krischan J, Margolis, David, Baker, Mark, Williams, Peter, Spreen, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809519/
http://dx.doi.org/10.1093/ofid/ofz360.2173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809519/
http://dx.doi.org/10.1093/ofid/ofz360.2173

Ejemplares similares